Roquefort Therapeutics plc (LON:ROQ)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 1.64M -24.6% |
| Revenue (ttm) | n/a |
| Net Income | -882.45K |
| EPS | -0.01 |
| Shares Out | 163.73M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40,046 |
| Average Volume | 811,225 |
| Open | 1.0000 |
| Previous Close | 1.0000 |
| Day's Range | 0.9550 - 1.0600 |
| 52-Week Range | 0.9000 - 3.0000 |
| Beta | -0.56 |
| RSI | 51.45 |
| Earnings Date | Apr 27, 2026 |
About Roquefort Therapeutics
Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in v... [Read more]
Financial Performance
Financial StatementsNews
Roquefort Therapeutics plc - Special Call
Roquefort Therapeutics plc - Special Call Company Participants Stephen West - Executive Chairman Edward Painter - Co-Founder, Chairman & CIO Sridhar Vempati - Co-Founder, Director, Chief Strategy Offi...